Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.CTYX · Entity 7637 | Director | November 28, 2017 | February 09, 2018 |
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | May 01, 2023 | May 02, 2023 |
| Fresh Tracks Therapeutics, Inc.BBI · Entity 90076 | Director | May 17, 2022 | May 17, 2022 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 26, 2023 | July 12, 2023 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date November 28, 2017 · Filed February 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Subscription Rights (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2017-11-21 | Direct | 0 |
Reported balance
After 2017-11-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-28 · Other · Disposed 1 · Balance 0 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. |
| Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.33 | Direct | 1 |
Reported balance
After 2017-11-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-28 · Other · Acquired 1 · Balance 1 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2: The Series B Preferred Stock has no expiration date. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2020-05-28 | Direct | 1,800 |
Reported balance
After 2017-11-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-28 · Other · Acquired 1,800 · Balance 1,800 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.
F2: The Series B Preferred Stock has no expiration date.
F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020.
Eledon Pharmaceuticals, Inc.
Report date May 01, 2023 · Filed May 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-05-01 | Direct | 150,437 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 150,437 · Balance 150,437 F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025.
Fresh Tracks Therapeutics, Inc.
Report date May 17, 2022 · Filed May 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2032-05-17 | Direct | 65,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 65,000 · Balance 65,000 |
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,284 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 1,284 · Balance 1,284 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $155.83 · Expires 2036-05-27 | Direct | 2,624 |
Reported balance
After 2026-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-27 · Grant · Acquired 2,624 · Balance 2,624 F3: Option vests in 12 monthly installments beginning June 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
F3: Option vests in 12 monthly installments beginning June 27, 2026.
RIGEL PHARMACEUTICALS INC
Report date May 26, 2023 · Filed July 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,000 |
Reported balance
After 2023-05-26 transaction · row 1
1 source rowRow 1 · 2023-05-26 · Grant · Acquired 25,000 · Balance 75,000 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2033-05-26 | Direct | 30,000 |
Reported balance
After 2023-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-26 · Grant · Acquired 30,000 · Balance 30,000 F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Travere Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,500 |
Ending reported balance
After 2026-08-18 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-08-17 · Exercise / conversion · Acquired 5,000 · Balance 66,500 Row 2 · 2026-08-17 · Sale · Disposed 1,900 · Balance 64,600 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F2: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 3 · 2026-08-17 · Sale · Disposed 2,600 · Balance 62,000 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F3: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-08-17 · Sale · Disposed 500 · Balance 61,500 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F4: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 5,000 · Balance 66,500 Row 6 · 2026-08-18 · Sale · Disposed 4,100 · Balance 62,400 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F5: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 7 · 2026-08-18 · Sale · Disposed 900 · Balance 61,500 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F6: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17 | Direct | 5,000 |
Reported balance
After 2026-08-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-17 · Exercise / conversion · Disposed 5,000 · Balance 5,000 F7: The stock option is fully vested and exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-08-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-18 · Exercise / conversion · Disposed 5,000 · Balance 0 F7: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
F2: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2023 Filed Sep 14, 2023 20:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $12.98 Strike: $12.98 | $64,900.00 |
DisclosureSEC source: 0001209191-23-049448 · doc4.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 22, 2014 and vested monthly over one year. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 20:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $115.02 | $575,120.00 |
DisclosureSEC source: 0001209191-23-049448 · doc4.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| September 12, 2023 Filed Sep 14, 2023 20:51 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,000 | $12.98 | $64,900.00 |
DisclosureSEC source: 0001209191-23-049448 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $12.98 Strike: $12.98 | $64,900.00 |
DisclosureSEC source: 0001209191-23-048383 · doc4.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2024-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 22, 2014 and vested monthly over one year. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $110.06 | $550,315.50 |
DisclosureSEC source: 0001209191-23-048383 · doc4.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 24, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,000 | $12.98 | $64,900.00 |
DisclosureSEC source: 0001209191-23-048383 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 208,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001140361-23-034287 · form4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-034287 · form4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031105 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest in full on May 17, 2024. F3 · derivative.expiration_date: The Restricted Stock Units will vest in full on May 17, 2024. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 4,290 | $0.00 Strike: $95.27 | $0.00 |
DisclosureSEC source: 0001209191-23-031105 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,290 Underlying: Common Stock · 4,290 shares Expires 2033-05-17 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 17, 2023. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 13,500 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-23-030959 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2033-05-16 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030959 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:44 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantCommon Stock · Derivative | 150,437 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026725 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,437 Underlying: Common Stock · 150,437 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 23:07 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006351 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 22:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $12.71 Strike: $12.71 | $190,650.00 |
DisclosureSEC source: 0001209191-22-055393 · doc4.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 23, 2013 and vested monthly over one year. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 22:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $114.76 | $1,721,403.00 |
DisclosureSEC source: 0001209191-22-055393 · doc4.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $113.21 to $115.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 22:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $12.71 | $190,650.00 |
DisclosureSEC source: 0001209191-22-055393 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 23:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $110.54 | $552,711.00 |
DisclosureSEC source: 0001209191-22-052894 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001140361-22-020305 · form4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-05-20 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020305 · form4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 9,724 | $0.00 Strike: $84.95 | $0.00 |
DisclosureSEC source: 0001209191-22-030951 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,724 Underlying: Common Stock · 9,724 shares Expires 2032-05-18 F1 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 18, 2022. Read SEC document |
| May 17, 2022 Filed May 17, 2022 17:15 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0000819050-22-000072 · wf-form4_165282206394146.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-05-17 Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:24 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001209191-22-028694 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-05-10 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:24 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028694 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $6.66 Strike: $6.66 | $99,900.00 |
DisclosureSEC source: 0001209191-22-025824 · doc4.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted May 23, 2012 and vested monthly over one year. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,000 | $92.76 | $1,391,392.50 |
DisclosureSEC source: 0001209191-22-025824 · doc4.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.53 to $93.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $6.66 | $99,900.00 |
DisclosureSEC source: 0001209191-22-025824 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:33 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006476 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:34 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $105.06 | $525,293.50 |
DisclosureSEC source: 0001209191-21-060283 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 16:43 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000819050-21-000084 · wf-form4_162370339855730.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-14 Read SEC document |
| June 10, 2021 Filed Jun 15, 2021 00:25 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $100.27 | $1,002,743.00 |
DisclosureSEC source: 0001209191-21-040445 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.04 to $100.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 8,833 | $0.00 Strike: $92.35 | $0.00 |
DisclosureSEC source: 0001209191-21-034376 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,833 Underlying: Common Stock · 8,833 shares Expires 2031-05-19 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 19, 2021. Read SEC document |
| May 19, 2021 Filed May 22, 2021 00:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001179110-21-005765 · edgar.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-19 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 19, 2021 Filed May 22, 2021 00:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005765 · edgar.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:22 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-21-033852 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-05-13 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:22 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033852 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 02:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 400 | $120.00 | $48,000.00 |
DisclosureSEC source: 0001209191-21-005823 · doc4.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,697 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 02:53 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,600 | $120.03 | $192,046.56 |
DisclosureSEC source: 0001209191-21-005823 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,097 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · ownership.direct: The reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 18:32 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Tax withholdingCommon Stock | 5,967 | $0.78 | $4,654.26 |
DisclosureSEC source: 0001062993-21-000139 · form4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,762 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 17:06 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001062993-20-004555 · form4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-09-15 F2 · derivative.exercise_date: The stock options will vest 25% on September 15, 2021, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 17:06 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantCommon Stock | 11,934 | $0.81 | $9,666.54 |
DisclosureSEC source: 0001062993-20-004555 · form4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,729 F1 · shares: On September 15, 2020, the reporting person was granted 11,934 restricted stock units ("RSUs") in lieu of a portion of cash compensation as a director of Brickell Biotech, Inc. The RSUs are scheduled to vest on December 31, 2020 and will be settled in the form of one share of common stock for each RSU. F1 · price: On September 15, 2020, the reporting person was granted 11,934 restricted stock units ("RSUs") in lieu of a portion of cash compensation as a director of Brickell Biotech, Inc. The RSUs are scheduled to vest on December 31, 2020 and will be settled in the form of one share of common stock for each RSU. Read SEC document |
| September 11, 2020 Filed Sep 16, 2020 00:18 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 1,167.21 | $0.00 Strike: $500.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025172 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167.21 Underlying: Series X1 Convertible Preferred Stock · 1,167.21 shares Expires 2030-09-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 1,167.21 shares of the Issuer's Series X1 Convertible Preferred Stock, which will vest in equal monthly installments over two years, subject to the Reporting Person's continued service to the Issuer through each vesting date. The Reporting Person's ability to exercise the option will be subject to stockholder approval under Nasdaq Marketplace Rule 5635(c). F2 · derivative.underlying: Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:22 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Exercise / conversionRestricted Stock Units · Derivative | 692 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-004308 · form4.xml · derivative · entry 4 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 692 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020. F3 · derivative.expiration_date: These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:22 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Tax withholdingCommon Stock | 8,631 | $0.94 | $8,113.14 |
DisclosureSEC source: 0001062993-20-004308 · form4.xml · nonDerivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,795 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:22 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Tax withholdingCommon Stock | 346 | $0.94 | $325.24 |
DisclosureSEC source: 0001062993-20-004308 · form4.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,426 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:22 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Exercise / conversionCommon Stock | 692 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-20-004308 · form4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:09 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Exercise / conversionRestricted Stock Units · Derivative | 692 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-003648 · form4.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692 Underlying: Common Stock · 692 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020. F3 · derivative.expiration_date: These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:09 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Tax withholdingCommon Stock | 346 | $0.92 | $318.32 |
DisclosureSEC source: 0001062993-20-003648 · form4.xml · nonDerivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,080 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:09 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Exercise / conversionCommon Stock | 692 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-20-003648 · form4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 14:01 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Exercise / conversionRestricted Stock Units · Derivative | 691 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000144 · edgar.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,384 Underlying: Common Stock · 691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020. F3 · derivative.expiration_date: These RSUs were granted on February 14, 2020 and vest in installments through August 31, 2020. F4 · balance_after: The reporting person filed a Form 4 on June 5, 2020 which reported, among other transactions, the vesting on various dates of portions of a grant of RSUs made to the reporting person on February 14, 2020. Column 9 of Table II of that Form 4 incorrectly reported the number of unvested RSUs remaining from that grant following each such vesting. The number reported in this Column 9 of Table II of this Form 4 represents the correct number of unvested RSUs remaining from the February 14, 2020 grant following the vestings that were reported on the Form 4 filed on June 5, 2020, as well as the vesting that occurred on June 30, 2020 as reported on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.